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Mast cell proteases are believed to participate in the
basement membrane destruction in blistering diseases.
Thus, normal human skin specimens were incubated
with purified human skin tryptase or compound 48/
80 (a mast cell degranulator) for up to 24 h. Thereafter,
the specimens were studied immunohistochemically.
Tryptase caused, in the presence and absence of 1,10-
phenanthroline, focal dermal–epidermal separation
above laminin and almost complete disappearance of
the staining of the extra domain A region of cellular
fibronectin in and beneath the basement membrane.
The immunopositivity of the cell-binding region of
fibronectin, laminin, and collagens IV and VII, how-
ever, was unaltered. Compound 48/80 induced almost
complete dermal–epidermal separation above intact
laminin and only focal reduction in the extra domain
A region of cellular fibronectin staining. These altera-
tions by compound 48/80 were prevented partially
by Na-p-tosyl-L-lysine chloromethyl ketone or 1,10-
Alterations in mast cells and their proteases have beenreported in a number of pathologic skin conditions(Harvima et al, 1994), and increased mast cell numbershave been counted in a variety of chronic skin diseasessuch as scleroderma (Nishioka et al, 1987), psoriasis
(Harvima et al, 1993), and pemphigus (Levi-Schaffer et al, 1991).
In normal skin, mast cells can be found in contact with the
epidermis or inside it only on rare occasions, and the presence of
mast cells in the epidermis has been associated with chronic skin
inflammation (Green et al, 1977) such as psoriasis (Harvima et al,
1993) and chronic leg ulcer (Bolton and Montagna, 1993). Participa-
tion of mast cells in subepidermal blistering diseases has been
suggested as bullous pemphigoid is characterized by urticarial lesions
which appear before blister formation, and mast cells in early lesions
are hypogranulated and their granules are spread extracellularly
(Wintroub et al, 1978). Furthermore, increased histamine and
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phenanthroline alone but completely when both
inhibitors were present suggesting the involvement
of tryptic serine proteinases, probably also tryptase,
and metalloproteinases. Preventive effect of N-tosyl-
L-phenylalanine chloromethyl ketone was weak
suggesting minor function of chymotryptic serine
proteinases. When tryptase was incubated with heparin
and pure plasma fibronectin, an abrupt decrease in
the adherence of cultured keratinocytes on to plastic
surface coated with these substances and a gradual
plasma fibronectin cleavage to 173, 161, and 28 kDa
fragments in sodium dodecyl sulfate–polyacrylamide
gel electrophoresis were found. In conclusion, tryptase
can cause focal dermal–epidermal separation above
laminin in skin specimens but it is not known to what
extent the decreased keratinocyte adherence in vitro
and fibronectin cleavage are related to this dermal–
epidermal separation. Key words: bullous disease/extra-
cellular matrix/protease. J Invest Dermatol 113:567–573,
1999
tryptase levels in blister fluids of pemphigoid suggest mast cell
involvement (Katayama et al, 1984; Brockow et al, 1996). In
addition, a dermatitis herpetiformis-like lesion has been induced in
healthy-looking skin in some patients after compound 48/80
injection (Cox and Friedmann, 1991).
Human mast cells can be divided into three types according to
their protease composition in secretory granules: (i) Mast cells
containing only tryptase (MCT); (ii) mast cells with tryptase,
chymase, carboxypeptidase and a cathepsin G-like proteinase
(MCTC); and (iii) mast cells showing chymase and carboxypeptidase
but not tryptase (MCC). In normal human skin, the majority of
the mast cells belongs to the MCTC type (Irani et al, 1989, 1991;
Schechter et al, 1990; Weidner and Austen, 1993).
Skin mast cells can bind to laminin via their receptors suggesting
an interaction between mast cells and the basement membrane
(BM) (Walsh et al, 1991a). The proteases secreted by mast cells
upon degranulation could spread to more distant sites affecting the
BM by different mechanisms. Tryptase is able to cleave fibronectin,
and it probably activates type IV collagenase (Lohi et al, 1992).
Tryptase can activate prostromelysin to stromelysin that in turn
activates latent collagenase (Gruber et al, 1989). Moreover, tryptase
activates single-chain urinary-type plasminogen activator (pro-
urokinase) that could activate plasminogen to plasmin (Stack
and Johnson, 1994). Human skin chymotrypsin-like proteinases,
chymase and cathepsin G, have been shown to cause dermal–
epidermal (DE) separation at the level of lamina lucida (Briggaman
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et al, 1984). Chymase can also activate procollagenase (Saarinen
et al, 1994). These observations suggest that human mast cell
proteases could be involved in the destruction of the BM and
blister formation in skin diseases.
In normal skin, fibronectin is located in the dermal–epidermal
(DE) junction and connective tissue of dermis (Couchman et al,
1990). As a component of the BM, fibronectin promotes adhesion
and migration (O’Keefe et al, 1985) and inhibits the terminal
differentiation (Adams and Watt, 1989) of keratinocytes. Skin
tryptase has previously been reported to cleave fibronectin from
the pericellular matrix secreted by fibroblasts in vitro. Tryptase also
degrades the released fibronectin to fragments of 180, 160, and
27 kDa in size (Lohi et al, 1992). No studies are available, however,
to demonstrate the effect of exogenous or endogenous tryptase on
fibronectin present in the BM and dermal connective tissue. In
addition, although incubation of human skin specimens with
chymase, cathepsin G. and elastase leads to DE separation
(Briggaman et al, 1984), the effect of tryptase in this respect is not
known. Thus, the purpose of this study was to incubate normal
skin specimens with purified mast cell tryptase and with a mast cell
degranulator, compound 48/80, in the presence and absence of
protease inhibitors to investigate possible DE separation and reduc-
tion in fibronectin immunopositivity. The cleavage of fibronectin
was also studied electrophoretically. To clarify the possibility that
the tryptase–heparin complex (Goldstein et al, 1992) could affect
keratinocyte adherence on to the substratum, tryptase was incubated
with heparin and fibronectin before coating plastic surface for
subsequent adherence of cultured keratinocytes. The results suggest
that mast cell tryptase can participate in the BM destruction and
that it cleaves fibronectin and also causes reduced keratinocyte
adherence.
MATERIALS AND METHODS
Chemicals Tris(hydroxymethyl)aminomethane, 3,39-diaminobenzidine,
poly L-lysine, bovine serum albumin, compound 48/80, Nα-p-tosyl-L-
lysine chloromethyl ketone (TLCK, an inhibitor of tryptic serine pro-
teinases), N-tosyl-L-phenylalanine chloromethyl ketone (TPCK, an
inhibitor of chymotryptic serine proteinases), 1,10-phenanthroline (a
metalloproteinase inhibitor) (Salvesen and Nagase, 1989), and heparin
sodium salt from porcine intestinal mucosa were obtained from Sigma
(St Louis, MO). Reagents for immunohistochemical staining, mouse
monoclonal anti-collagen type VII antibody, rabbit polyclonal anti-laminin
antibody, and rabbit polyclonal anti-collagen type IV antibody were
purchased from Chemicon International (Temecula, CA). Mouse mono-
clonal antibody specific to the extra domain A region of cellular fibronectin
(EDA-cFn) (Vartio et al, 1987) was purchased from Biohit OY (Helsinki,
Finland). Pure fibronectin from human plasma (pFn) and mouse monoclonal
anti-fibronectin antibody directed towards the cell-binding region (this
antibody recognizes both cellular and soluble fibronectins) were purchased
from Boehringer Mannheim GmbH (Mannheim, Germany).
Mast cell tryptase (285 µg per ml, active center concentration 4.22 µM)
was purified to homogeneity from healthy-looking human skin as described
previously (Harvima et al, 1988, 1995).
Human skin preparation and incubation Healthy-looking skin was
obtained as a left-over material from breast carcinoma operations of four
individuals. Thin, split-thickness skin strips containing intact epidermis and
upper dermis were cut at approximately 0.4 cm wide and 2 cm long
pieces. The time from skin removal to the initiation of incubation did not
exceed 2 h in any experiment. The skin specimens were placed in 1.5 ml
Eppendorf polypropene tubes, two pieces per tube, containing 300 µl of
28.5 µg skin tryptase per ml, 50 µg heparin per ml, 140 mM NaCl, and
10 mM Tris–HCl buffer, pH 7.6. The presence of a sufficient amount of
heparin during incubation is essential to prevent rapid and irreversible
inactivation of tryptase in low salt conditions (Harvima et al, 1988, 1995).
In addition, 1 mM 1,10-phenanthroline or deionized water as its control
solution was included in the mixture, which was then incubated at 37°C.
This experiment was performed three times for varying time periods (2
and 8 h, 4 and 24 h, and 12 and 24 h). In another experiment, skin
specimens were incubated with 10 µg compound 48/80 per ml at pH 7.6,
in the presence or absence of 1 mM TLCK, 1 mM TPCK, and/or
1 mM 1,10-phenanthroline. This experiment was performed twice with
incubation times of 4 and 24 h, and 12 and 24 h. After the incubation,
the treated skin specimens were immediately embedded in OCT compound
(Miles Scientific, Naperville, IL) and frozen in isopentane cooled with a
mixture of absolute ethanol and dry ice for immunohistochemical studies.
Immunohistochemical staining methods For immunohistochemistry,
the skin sections were fixed in ice cold acetone for 15 min followed by
blocking with 100 µg purified goat IgG per ml dissolved in 1% bovine
serum albumin and phosphate-buffered saline. The bound monoclonal
anti-EDA-cFn (0.5 µg per ml), anti-Fn (cell-binding region) (2 µg per
ml), and anti-collagen VII (1:50) as well as polyclonal anti-laminin (1:500)
and anti-collagen IV (1:1000) antibodies on skin sections were visualized
with the avidin–biotin–peroxidase (ABC) technique using the Vectastain
Elite ABC kit (Vector) together with 0.05% 3,39-diaminobenzidine tetra-
hydrochloride, 0.04% nickel chloride and 0.03% hydrogen peroxide. The
specificity of the staining was controlled on sections from the same skin
specimen with unrelated polyclonal or monoclonal antibodies (purified
IgG of the same species; Sigma) in higher concentrations than the specific
antibodies.
Incubation of pFN with tryptase and heparin for subsequent
electrophoresis and keratinocyte adherence Mast cell tryptase in the
final concentrations of 17, 1.7, and 0.17 µg per ml was incubated together
with 80 µg heparin per ml (to prevent rapid inactivation of tryptase;
Harvima et al, 1988) and 60 µg pFn per ml at pH 7.6, at 37°C, for 24
and 48 h. After the incubation, the mixture was immediately divided
and frozen for subsequent electrophoresis and keratinocyte adherence
experiments. This experiment was performed twice.
Electrophoresis For electrophoresis, samples from tryptase and pFn
incubation were precipitated in 10% trichloroacetic acid (final concentra-
tion) on an ice bath for 30 min followed by centrifugation (80003g,
Eppendorf table centrifuge) for 10 min at room temperature. The pre-
cipitates were washed twice with an equal volume of ice-cold acetone at
–20°C for 30 min, centrifuged for 5 min, and air-dried at room temperature.
The precipitates were dissolved in 10 µl of electrophoresis buffer (10 mM
Tris–HCl, pH 8, 1 mM ethylenediamine tetraacetic acid, 2.5% sodium
dodecyl sulfate (SDS), 5% β-mercaptoethanol and 0.01% bromophenol
blue) followed by denaturation at 100°C for 5 min. The samples were
subjected to SDS–polyacrylamide gel electrophoresis (PAGE) on a 7.5%
Pharmacia Phastgel according to manufacturer’s instructions (Pharmacia
PhastSystem, Pharmacia, Uppsala, Sweden) and the gels were stained with
Coomassie R350. Both low molecular weight and high molecular weight
standards from Pharmacia were used to estimate molecular sizes.
Culture of keratinocytes The allogeneic foreskin samples from young
boys (Harvima et al, 1999) were stored for less than 5 d in a refrigerator
in Keratinocyte-SFM (Gibco BRL, Life Technologies, Paisley, Scotland,
U.K.) serum-free medium together with 100 µg streptomycin per ml,
100 U penicillin per ml, and 2.5 µg Fungizone per ml (Gibco). The tissue
specimens were washed with Dulbecco’s phosphate-buffered saline (Gibco)
followed by incubation in a refrigerator with 2.4 U dispase per ml
(Boehringer) overnight. The epidermis was then easily separated from the
dermis by using forceps. The epidermis was further processed by incubating
it in 0.05% trypsin and 0.02% ethylenediamine tetraacetic acid (Viralex,
PAA Laboratories GmbH, Linz, Austria) to release proliferating basal
keratinocytes. After centrifugation, the cells were cultured in Keratinocyte-
SFM medium supplemented with 5 ng epidermal growth factor per ml,
50 µg bovine pituitary extract per ml, 100 µg streptomycin per ml, and
100 U penicillin per ml, at 37°C and 5% CO2, until subconfluence.
Following detachment from the plastic surface with 0.05% trypsin and
0.02% ethylenediamine tetraacetic acid the cells were subcultured and
expanded. Keratinocyte passages 3–8 were used in subsequent experiments
and the viability was always over 90%.
Keratinocyte adherence experiment For keratinocyte adherence
experiments, 175 µl of the incubation mixture containing tryptase, heparin
and/or pFn (see above) was added into a well of 24-well plate (Falcon,
Becton Dickinson, Meylau Cedex, France) at 37°C for 2.5 h. Each
incubation mixture was studied in quadruplicate wells and the experiment
was performed twice. After the incubation, the wells were extensively
washed twice with Dulbecco’s phosphate-buffered saline followed by
adding 15,000 keratinocytes (in Keratinocyte-SFM medium without epi-
dermal growth factor and bovine pituitary extract) into each well for 4 h,
at 37°C and 5% CO2 (O’Keefe et al, 1985). Thereafter, the nonadhering
keratinocytes were washed away with Dulbecco’s phosphate-buffered saline,
and the bound cells were fixed in 4% formaldehyde overnight. Finally, the
cells were stained with hematoxylin. The total number of adhered cells
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Table I. DE separation and immunostaining of EDA-cFn after the treatment of normal skin specimens with purified skin
tryptasea
Incubation time
Incubation mixture 2 h 4 h 8 h 12 h 24 h
Control 11 11 11 11 11
no DE sep no DE sep no DE sep no DE sep no DE sep
Tryptase 11 11 1 1 –
no DE sep no DE sep DE sep1 DE sep1 DE sep1
Tryptase and 1,10-phen 11 11 1 1 –
no DE sep no DE sep no DE sep no DE sep DE sep1
1,10-phen 11 11 11 11 11
no DE sep no DE sep no DE sep no DE sep no DE sep
aThe intensity of the EDA-cFn immunostaining was graded as: ‘‘–’’ 5 very weak or no apparent staining; ‘‘1’’ 5 moderate or focal staining in the BM zone; and ‘‘11’’ 5
clear linear staining. Dermal–epidermal separation (DE sep) in the BM zone was graded as: ‘‘no DE sep’’ 5 no apparent DE separation; ‘‘DE sep 1’’ 5 focal DE separation;
‘‘DE sep 11’’ 5 complete or near complete DE separation. 1,10-phen 5 1 mM 1,10-phenanthroline. Tryptase concentration in the incubation mixture was 28.5 µg per ml
and heparin concentration was 50 µg per ml.
and the percentage of these cells displaying spread appearance were
measured in seven high power fields/well systemically but beginning the
counting from a random site. Spread and unspread cells were identified as
described previously (O’Keefe et al, 1985).
RESULTS
Incubation of skin specimens with purified tryptase leads to
focal dermal–epidermal separation and decrease in EDA-
cFn staining Three individual experiments were performed to
study the effect of purified tryptase in the presence of heparin on
DE separation and immunostaining of fibronectin, laminin, and
type IV and type VII collagens. The results on the DE separation
and EDA-cFn immunostaining have been summarized in Table I.
Focal separation of the DE junction by tryptase alone was apparent
at 8 h, which, however, did not progress to full separation even
after 24 h. When tryptase was combined with 1 mM 1,10-
phenanthroline to exclude possible metalloproteinase activation and
action (Gruber et al, 1989; Salvesen and Nagase, 1989; Lohi et al,
1992), essentially similar results were obtained but the focal DE
separation (Fig 1) could be seen clearly later, i.e., at 24 h at the
earliest (Table I). In all tryptase-treated and control skin specimens,
no apparent decrease in the immunostaining of laminin and
collagens IV and VII was observed. These stainings were linear in
the BM zone, and they were observed in the tryptase-treated
specimens on the dermal side after focal DE separation (Fig 1).
Control specimens revealed no DE separation by 24 h (Table I,
Fig 2).
The intensity of the EDA-cFn staining remained unchanged
when the skin specimens were incubated without (Fig 2) or with
1 mM 1,10-phenanthroline for up to 24 h. Incubation of skin
specimens with tryptase alone or with tryptase together with
1,10-phenanthroline resulted in clear decrease in the EDA-cFn
immunostaining in the BM zone of skin and blood vessels as well
as in the connective tissue of the uppermost dermis after an 8 h
incubation. After 24 h the staining had practically disappeared
(Fig 3).
The immunostaining of the cell-binding region of Fn was,
besides linear in the BM zone, also reticular in the dermis in
control samples. Incubation of skin specimens in tryptase solution,
with or without 1,10-phenanthroline, did not result in apparent
decrease of this immunostaining (Fig 4). In the area of focal DE
separation, the immunostaining was localized on to the dermal
side (Fig 4).
Incubation of skin specimens with compound 48/80 results
in dermal–epidermal separation and focal decrease in EDA-
cFn staining Two individual experiments were performed to
study the effect of endogenous mast cell proteases on DE separation
and immunostaining of fibronectin, laminin, and type IV and type
VII collagens after the degranulation of mast cells by compound
48/80. The results of the DE separation and EDA-cFn immuno-
staining have been summarized in Table II.
Figure 1. Focal separation of epidermis from dermis by tryptase
but clear linear staining of laminin on the dermal side in the BM
zone. A healthy-looking skin specimen was incubated in the presence of
28.5 µg tryptase per ml, 50 µg heparin per ml, and 1 mM 1,10-
phenanthroline for 24 h followed by immunostaining of laminin. Note
the laminin staining on the dermal side (arrows). Scale bar: 50 µm.
Figure 2. Incubation of skin specimen without tryptase and 1,10-
phenanthroline shows intact dermal–epidermal junction and EDA-
cFn staining. A healthy-looking skin specimen was incubated in the
absence of tryptase and 1,10-phenanthroline for 24 h. Thereafter, a skin
section was immunostained for the EDA region of cFn. Note the clear
linear staining in the BM zone (arrows) and reticular staining beneath it.
Scale bar: 50 µm.
Clear EDA-cFn immunostaining was seen in control skin speci-
mens without any apparent DE separation up to 24 h (see also
Fig 2). The treatment of skin specimens with compound 48/80
alone resulted in almost complete DE separation, but laminin which
was unaffected was localized on to the dermal side (Fig 5). Owing
to compound 48/80, also the EDA-cFn immunostaining showed
clear focal reduction in the BM zone (Table II), which could be
a consequence of the action of tryptase, chymase, and/or activated
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Figure 3. Disappearance of the EDA-cFn staining by tryptase in
the presence of 1,10-phenanthroline. A healthy-looking skin specimen
was incubated in the presence of tryptase and 1 mM 1,10-phenanthroline
for 24 h. Thereafter, a skin section was immunostained for the EDA region
of cFn. Note the complete absence of staining in the dermal–epidermal
junction and immediately beneath it (arrows), but still some staining is
present in the dermis (arrowhead). Scale bar: 50 µm.
Figure 4. Staining of the cell-binding region of fibronectin is
unaffected and localized on to the dermal side after tryptase
treatment. A healthy-looking skin specimen was incubated in the presence
of tryptase and 1,10-phenanthroline for 24 h. Thereafter, a skin section
was immunostained for the cell-binding region of fibronectin. In the BM
zone and on the dermal side in areas of dermal–epidermal separation, the
unaffected staining is linear (arrow). Scale bar: 25 µm.
Table II. DE separation and immunostaining of EDA-cFn
after the incubation of normal skin specimens with
compound 48/80 (a mast cell degranulator)a
Incubation time
Incubation mixture 4 h 12 h 24 h
Control 11 11 11
no DE sep no DE sep no DE sep
Compound 48/80 11 11 1
no DE sep DE sep1 DE sep11
Compound 48/80 11 11 11
1 TLCK no DE sep DE sep1 DE sep1
Compound 48/80 11 11 1
1 TPCK no DE sep DE sep1 DE sep11
Compound 48/80 11 11 1
1 1,10-phen no DE sep DE sep1 DE sep1
Compound 48/80 11 11 11
1 TLCK 1 1,10-phen no DE sep no DE sep no DE sep
Compound 48/80 11 11 1
1 TPCK 1 1,10-phen no DE sep no DE sep DE sep1
aThe intensity of the EDA-cFn immunostaining was graded as: ‘‘–’’ 5 very weak
or no apparent staining; ‘‘1’’ 5 focal decrease in the staining of the BM zone; and
‘‘11’’ 5 clear linear staining. Dermal–epidermal separation (DE sep) in the BM
was graded as: ‘‘no DE sep’’ 5 no apparent DE separation; ‘‘DE sep 1’’ 5 focal DE
separation; ‘‘DE sep 11’’ 5 complete or near complete DE separation. 1,10-phen 5
1 mM 1,10-phenanthroline. TLCK 5 1 mM Nα-p-tosyl-L-lysine chloromethyl
ketone. TPCK 5 1 mM N-tosyl-L-phenylalanine chloromethyl ketone.
Figure 5. Almost complete separation of epidermis from dermis
by compound 48/80, but unaltered laminin staining is localized on
to the dermal side. A section from healthy-looking skin specimen
after 24 h incubation with compound 48/80 alone. The section was
immunostained for laminin. Note the clear linear immunostaining of
laminin on the dermal side of the BM zone and almost complete dermal–
epidermal separation (arrows). Scale bar: 50 µm.
Figure 6. Only focal dermal–epidermal separation and preserved
EDA-cFn staining after incubation with compound 48/80 and
TLCK. A section from healthy-looking skin specimen after 24 h incubation
with compound 48/80 and TLCK. The section was immunostained for
the EDA region of cFn. Note that there is only focal dermal–epidermal
separation (arrows) and a consistent linear immunostaining in the BM zone
(arrowheads). Scale bar: 50 µm.
metalloproteinases (Briggaman et al, 1984; Gruber et al, 1989; Lohi
et al, 1992; Saarinen et al, 1994; Stack and Johnson, 1994).
Simultaneous inhibition of trypsin-like serine proteinases, including
tryptase (Harvima et al, 1988), by 1 mM TLCK upon mast
cell degranulation prevented the disappearance of the EDA-cFn
immunostaining and partially protected from the DE separation,
although focal DE separation was still observed (Table II, Fig 6).
The treatment of chymotrypsin-like enzymes, however, including
chymase (Powers et al, 1985), with TPCK had no apparent
effect on the EDA-cFn immunostaining and DE separation when
compared with the results obtained with compound 48/80 alone
(Table II). When only metalloproteinase action was abolished with
1 mM 1,10-phenanthroline (Salvesen and Nagase, 1989) at the
time of mast cell degranulation, focal decrease in the EDA-
cFn immunostaining and focal DE separation were still evident
(Table II). Combination of TLCK and 1,10-phenanthroline com-
pletely protected the skin from both the DE separation and
disappearance of the EDA-cFn immunostaining (Table II, Fig 7).
Combination of TPCK with 1,10-phenanthroline only delayed the
DE separation but did not prevent the focal disappearance of the
EDA-cFn immunostaining (Table II, Fig 8) when compared with
the result by 1,10-phenanthroline alone. The location of the focal
decrease in the EDA-cFn immunostaining, however, did not
consistently match with that of DE separation (Fig 8).
In all compound 48/80-treated and control skin specimens, no
apparent alterations in the immunostaining of laminin (Fig 5) or
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Figure 7. TLCK and 1,10-phenanthroline together prevent the
effects of compound 48/80. A section from healthy-looking skin
specimen after 24 h incubation with compound 48/80, TLCK and 1,10-
phenanthroline. The section was immunostained for the EDA region of
cFn. Note the clear linear immunostaining along the BM zone (arrow) and
absence of any apparent dermal–epidermal separation. Scale bar: 50 µm.
Figure 8. Focal dermal–epidermal separation and focal decrease in
the EDA-cFn staining by compound 48/80 in the presence of
TPCK and 1,10-phenanthroline. A section from healthy-looking skin
specimen after 24-h incubation with compound 48/80, TPCK and 1,10-
phenanthroline. The section was immunostained for the EDA region of
cFn. Note the focal decrease in the immunostaining in the BM zone
(arrowheads) and focal dermal–epidermal separation (arrows), which, however,
are not colocalized in the same area. Scale bar: 50 µm.
collagens IV and VII were observed (data not shown). These
stainings were linear in the BM zone, and they localized on to
the dermal side after DE separation (Fig 5). In addition, the
immunostaining of the cell-binding region of Fn remained quite
unchanged when compound 48/80 was added alone or with
proteinase inhibitors to the incubation mixture. This immuno-
staining was also localized on to the dermal side after DE separation.
pFN is cleaved by tryptase in vitro Incubation of pFn with
mast cell tryptase resulted in the cleavage of pFn which was dose-
dependent by tryptase. After SDS–PAGE under reducing conditions
the pFn double bands of 225 kDa and 215 kDa in size were
degraded to 173 kDa, 161 kDa and 28 kDa fragments (Fig 9). The
same result was observed after 24 h and 48 h incubation periods.
Decreased adherence and spreading of keratinocytes on a
plastic surface coated with a mixture of tryptase, heparin,
and fibronectin After the incubation of pFn with tryptase and
heparin for 24 h and 48 h, one-half of the incubation mixture was
processed for SDS–PAGE (see above, Fig 9) and the second half
for keratinocyte adherence experiments (Table III).
By increasing the tryptase concentration, the number of adhered
keratinocytes decreased in a concentration-dependent manner
(Table III). Already at very low concentration (0.17 µg per ml)
in relation to heparin (80 µg per ml) and pFn (60 µg per ml),
tryptase reduced significantly the number of adhered keratinocytes
by 30–40% (Table III) (p , 0.0001, t test, n 5 8, the values from
two experiments combined together) without causing any apparent
Figure 9. Cleavage of pFn by tryptase. pFn was treated with various
concentrations of skin tryptase for 24 h followed by SDS–PAGE under
reducing conditions. Lane 1, low-molecular weight markers (94, 67, and
43 kDa); lane 2, high-molecular weight markers (212, 170, 116, 76, and
53 kDa); lane 3, pFn 1 control (bands 225 and 215 kDa);
lane 4, pFn 1 0.17 µg tryptase per ml (bands 225 and 215 kDa);
lane 5, pFn 1 1.7 µg tryptase per ml (cleavage product 195 kDa);
lane 6, pFn 1 17 µg tryptase per ml (cleavage products 173, 161, and
28 kDa). The highest concentration of tryptase (17 µg per ml, lane 6)
under these experimental conditions showed only very weak bands in
SDS–PAGE (see also Harvima et al, 1988) using Pharmacia 7.5%
polyacrylamide gels (data not shown).
degradation of pFn (Fig 9). This suggests a direct interfering effect
of tryptase protein on heparin–pFn-mediated cell adherence. By
increasing the tryptase concentration to 1.7 µg per ml, pFn was
cleaved to a 195 kDa fragment (Fig 9), and simultaneously maximal
decrease in keratinocyte adherence was reached. The number of
adhered cells in these coated wells was even significantly lower
than that in the control wells without pFn, tryptase, and heparin
(p 5 0.013, n 5 8) (Table III), which suggests that, besides
degraded pFn, also tryptase protein could reduce cell adherence.
Further increase in the tryptase concentration to 17 µg per ml did
not yield additional effect on keratinocyte adherence, but it
decreased significantly the percentage of adhered cells showing the
spread appearance (p , 0.0001, n 5 8) (Table III) and further
degraded pFn to smaller fragments (Fig 9). Essentially similar results
were obtained regardless of the 24 h or 48 h incubation time.
DISCUSSION
Basement membrane is composed of two major regions, lamina
densa and lamina lucida, which contain, e.g., collagen IV, laminin,
and fibronectin (Marinkovich, 1993). Previous studies have sug-
gested that skin mast cells and their proteases may be involved in
the BM cleavage and blister formation in subepidermal bullous
diseases (Wintroub et al, 1978; Briggaman et al, 1984; Brockow
et al, 1996). The degranulation of mast cells could be a result of
complement activation and formation of anaphylatoxins C3a and
C5a (Kubota, 1992). Also neuropeptides and cytokines can induce
mast cell degranulation (van Overveld et al, 1991; Huttunen et al,
1996). Although mast cells are not in a direct morphologic contact
with the BM, released granules and protease–heparin proteoglycan
complexes (Goldstein et al, 1992) could reach this zone resulting
in cleavage of the BM components directly (Briggaman et al, 1984;
Lohi et al, 1992) or indirectly via activation of collagenolytic
metalloproteinases (Gruber et al, 1989; Lohi et al, 1992; Saarinen et al,
1994). The well-known interaction between heparin-proteoglycan
and the heparin-binding region of fibronectin (Couchman et al,
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Table III. Incubation of purified skin tryptase with pFN and heparin for 24 h before coating the plastic surface for
subsequent keratinocyte adherencea
Incubation mixture
Heparin Tryptase Fibronectin Keratinocyte adherence Keratinocyte spread
(80 µg per ml) (µg per ml) (60 µg per ml) (cells per cm2) (% of adhered cells)
1 0 1 1751 6 205 95.6 6 2.0
1 0.17 1 1227 6 86 94.1 6 3.0
1 1.7 1 687 6 98 93.3 6 0.6
1 17 1 641 6 141 82.9 6 7.3
– 0 – 895 6 65 77.0 6 4.6
aThe keratinocyte adherence and spread experiment was done in quadruplicate wells and the results are expressed as mean 6 SD. The results are from one
representative experiment.
1990; Mohri, 1996) may be important for the movement and
attack of heparin-complexed mast cell proteases to the BM.
Previously, incubation of normal skin specimens with up to 70–
100 nM chymase has been found to lead to complete DE separation
at the level of lamina lucida, and between laminin and bullous
pemphigoid antigen, by 8 h at 36°C. No apparent decrease in
immunofluorescent staining of these antigens, however, was
noticed. On the other hand, cathepsin G produced similar but only
focal DE separation (Briggaman et al, 1984). Likewise, in this study,
422 nM tryptase caused focal DE separation, laminin on the dermal
side, already by 8 h at 37°C, but the separation did not further
progress to completion by 24 h. Furthermore, a part of this effect
can be attributed to metalloproteinases, probably to activated ones,
as 24 h was needed for the same effect when 1,10-phenanthroline
was present in the incubation mixture. As found out previously
with chymase (Briggaman et al, 1984), no apparent decrease in
laminin or collagens IV and VII staining by tryptase was observed.
Degranulation of mast cells in skin specimens with compound
48/80, at pH 7.6, resulted in almost complete DE separation in
24 h, but intact laminin and collagens IV and VII were found on
the dermal side. This can be due to direct effects of released
endogenous tryptase, chymase, and cathepsin G on the BM, and/
or due to indirect effects via activation of fibroblasts with several
mast cell mediators (Walsh et al, 1991b; Berman and Wietzerbin,
1992; Gruber et al, 1997) and activation of collagenolytic metallo-
proteinases. Also other, less characterized proteases from plasma
and different stimulated skin cells may be involved, too. As TPCK
exerted relatively weak protective effects on DE separation both
in the presence and absence of 1,10-phenanthroline (Table II),
the function of chymase and cathepsin G under these experimental
conditions does not seem to be marked. Probably chymase–heparin
proteoglycan complexes are too large (Goldstein et al, 1992), and
thus their diffusion in extracellular matrix is slow. Alternatively,
chymase could be inactivated rapidly by protease inhibitors present
in mast cells (Schechter et al, 1989; Harvima et al, 1993; Kaminska
et al, 1996). In addition, possible toxic effects of the used proteinase
inhibitors on cells should be remembered (Salvesen and Nagase,
1989), although the modulatory effects of TPCK on results were
minimal when compared with those of TLCK. Both TLCK and
1,10-phenanthroline partially protected from the DE separation,
but combination of these two inhibitors completely abolished the
DE separation suggesting a major role for trypsin-like serine
proteinases, such as tryptase among others (Harvima et al, 1988,
1995), and metalloproteinases. Although TLCK is known to be
able to inhibit acidic thiol proteinases too (Salvesen and Nagase,
1989), the used pH 7.6 does not favor the function of these
proteinases. Tryptase–heparin proteoglycan complexes are smaller
than chymase–heparin proteoglycan complexes, and thus the former
complexes could diffuse away from mast cells (Goldstein et al,
1992). Furthermore, no physiologic inhibitor for tryptase is known
(Harvima et al, 1995), which allows a prolonged action time for
this enzyme.
Fibronectin is widely distributed in plasma and in other body
fluids (pFn) and also in tissues in an insoluble form (cFn) produced
locally by several different cell types. Fibronectin is a 450 kDa
dimer consisting of two similar but not identical disulfide-bonded
225 kDa subunits. cFn differs from pFn by its EDA or EDB
regions, although the structures and properties of cFn and pFn are
similar (Couchman et al, 1990; Mohri, 1996). The biologic function
of the EDA region in cFn is not well known but it is suggested to
upregulate integrin-binding affinity of cFn and, thus, enhance the
binding of cells to matrix (Manabe et al, 1997). Incubation of skin
specimens with mast cell tryptase resulted in a clear disappearance
of the EDA-cFn immunostaining after 24 h incubation, even in
the presence of 1,10-phenanthroline pointing to the direct effect
of tryptase. This is in accordance with the previous finding that
tryptase can cleave fibronectin from the pericellular matrix deposited
by fibroblasts (Lohi et al, 1992). The immunostaining of the cell-
binding region of fibronectin, however, was unaltered suggesting
that fibronectin was still present in the BM zone and dermal
connective tissue, although in a degraded form. This is supported
by the previous finding showing fibronectin cleavage by tryptase
(Lohi et al, 1992) and also by the present finding showing similar
pFn cleavage products (Fig 9). As heparin can bind tightly to
fibronectin affecting its cell-binding properties (Ruoslahti, 1988)
and also to tryptase preventing its rapid dissociation from a tetramer
to inactive monomers (Harvima et al, 1995) a very complex
interaction between these molecules and keratinocyte binding is
likely. Nevertheless, the combination of tryptase with heparin and
pFn led to an abrupt decrease in keratinocyte adherence on to the
coated plastic surface (Table III) showing the potency of tryptase
already at low concentration. A part of this effect can be attributed
to degraded less-functional pFn, but tryptase protein itself could
also interfere with the interaction between keratinocytes and pFn–
heparin complex. The detailed mechanisms, however, need to be
studied in future.
When endogenous mast cell proteases in skin specimens were
released by compound 48/80, neither TPCK nor 1,10-phenanthro-
line could prevent the focal decrease in the EDA-cFn immuno-
staining in the BM zone (Fig 8). By comparison, TLCK alone or
in combination with 1,10-phenanthroline completely inhibited the
disappearance in the EDA-cFn staining (Table II) suggesting the
involvement of trypsin-like serine proteinases such as mast cell
tryptase (Harvima et al, 1988). As was found with purified tryptase,
the immunopositivity of the cell-binding region of fibronectin was
also unaltered by compound 48/80.
The present results show that mast cell tryptase, either alone or
in combination with metalloproteinases, can participate in the
destruction of the BM, and one structural target is at least fibronec-
tin. Also other, yet unidentified, matrix components may be affected
as well. The decrease in the EDA-cFn staining suggests that one
cleavage site is located in this region, which may lead to a decrease
in adherence of keratinocytes and also that of other dermal cells to
fibronectin (Manabe et al, 1997). Nevertheless, this decrease in the
EDA-cFn staining did not consistently colocalize with the focal
DE separation in the DE junction (Figs 3 and 8), and their time
course for appearance was different (Tables I and II), which
indicates that these phenomena are not closely related to each other.
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The immunopositivity of the cell-binding region was unaltered
suggesting preservation of this structure and a retained ability of
keratinocytes to adhere. The incubation of tryptase with pFn and
heparin, however, resulted in decreased keratinocyte adherence on
to the coated plastic surface. The mechanism and the structural
target(s) leading to the focal DE separation above laminin by
tryptase are not clear. Although tryptase can reduce keratinocyte
adherence and degrade fibronectin in vitro it is not known to what
extent these activities of tryptase are related to its ability to induce
DE separation.
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